Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …

Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Purpose To investigate the effect of adding concurrent chemotherapy (CT) to cetuximab plus
radiotherapy (RT; CT-cetux-RT) compared with cetuximab plus RT (cetux-RT) in locally …

PURPOSE We performed an open-label randomized controlled phase III study comparing
treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus …

Purpose Combining cisplatin or cetuximab with radiation improves overall survival (OS) of
patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum …

PURPOSE: To report toxicity data from the first 13 consecutive patients with locally
advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin …

Purpose Both concurrent chemoradiotherapy (CT-RT) and cetuximab radiotherapy (cetux-
RT) have been established as the standard of care for the treatment of locally advanced …